Halozyme Therapeutics (HALO) Goodwill (2022 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Goodwill of $582.3 million for Q1 2026, up 39.71% year-over-year from $416.8 million in Q1 2025, and little changed quarter-over-quarter from $580.4 million in Q4 2025.
Halozyme Therapeutics (HALO) Goodwill (2022 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Goodwill for 5 consecutive years, with $582.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Goodwill rose 39.71% year-over-year to $582.3 million; the TTM figure through Mar 2026 stood at $582.3 million (up 39.71% YoY), while the FY2025 annual figure was $580.4 million, up 39.23% from the prior year.
- Goodwill was little changed at $582.3 million in Q1 2026 per HALO's latest filing, from $580.4 million in the prior quarter.
- Across five years, Goodwill topped out at $582.3 million in Q1 2026 and bottomed at $199.5 million in Q2 2022.
- Historically, Goodwill has averaged $409.7 million across 5 years, with a median of $416.8 million in 2023.
- Annual changes were most pronounced in 2023 — Goodwill jumped 108.95% — and 2024, when it changed 0.0%.
- Halozyme Therapeutics' Goodwill stood at $409.0 million in 2022, then increased by 1.9% to $416.8 million in 2023, then changed by 0.0% to $416.8 million in 2024, then surged by 39.23% to $580.4 million in 2025, then grew by 0.34% to $582.3 million in 2026.
- Business Quant data shows HALO's Goodwill at $582.3 million in Q1 2026, $580.4 million in Q4 2025, and $416.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 581.73 Mn |
| Mar 31, 2026 | 582.32 Mn |
| Dec 31, 2025 | 580.36 Mn |
| Sep 30, 2025 | 416.82 Mn |
| Jun 30, 2025 | 416.82 Mn |
| Mar 31, 2025 | 416.82 Mn |
| Dec 31, 2024 | 416.82 Mn |
| Sep 30, 2024 | 416.82 Mn |
| Jun 30, 2024 | 416.82 Mn |
| Mar 31, 2024 | 416.82 Mn |
| Dec 31, 2023 | 416.82 Mn |
| Sep 30, 2023 | 416.82 Mn |
| Jun 30, 2023 | 416.82 Mn |
| Mar 31, 2023 | 416.22 Mn |
| Dec 31, 2022 | 409.05 Mn |
| Sep 30, 2022 | 199.48 Mn |
| Jun 30, 2022 | 199.48 Mn |